Multisystem sarcoidosis in a patient on interferon-α therapy for chronic hepatitis C

Oudghiri, Bouchra; Benzagmout, Mohammed; Boujraf, Saïd; Belahcen, Faouzi; Ibrahimi, A.

doi:10.4103/0974-777x.96779

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After initiation of IFN-α therapy, the average duration of sarcoidosis onset was 7.9 months (range 2–14 months; Table 1 ). IFN-α therapy was discontinued in 16 patients, and most of them showed improvement after systemic corticosteroid treatment; however, one patient died because of central nervous system disease (Table 1 ) [ 8 ]. Six cases of IFN-β-induced sarcoidosis are presented in Table 2 .…”

Section: Discussionmentioning

confidence: 99%

Interferon-induced sarcoidosis with uveitis as the initial symptom: a case report and review of the literature

2021

View full text Add to dashboard Cite

Background In recent years, numerous studies have reported the development or exacerbation of sarcoidosis due to interferon therapy. However, ocular lesions rarely present as initial symptoms. Herein, we describe a rare case of interferon-α-induced sarcoidosis with uveitis as the initial symptom, and present a review of the relevant literature. Case presentation This case involved a 62-year-old-Japanese woman with a history of a combination treatment of pegylated interferon-α-2a, ribavirin, and simeprevir, after which she developed granulomatous panuveitis. She was subsequently diagnosed with sarcoidosis following histological examination of skin biopsy specimens. In addition to reporting this case, we performed a literature review of 27 cases (24 case reports) of histopathologically diagnosed interferon-α-induced sarcoidosis published between January 2009 and November 2018. Conclusions Among the reviewed cases, 23 (85.1%) cases developed skin lesions and 19 (70.1%) had lung lesions. Only three cases (11.1%) had accompanying eye lesions. Interferon-α therapy was discontinued in 16 cases (52.9%), and the majority exhibited improvement after systemic corticosteroid treatment. There are few reported cases of interferon-α-induced sarcoidosis with uveitis as the initial symptom. However, if uveitis develops during or after interferon-α treatment, it might represent an initial symptom of interferon-α-induced sarcoidosis, as observed in the present case.

show abstract

Section: Discussionmentioning

confidence: 99%

Interferon-induced sarcoidosis with uveitis as the initial symptom: a case report and review of the literature

2021

View full text Add to dashboard Cite

show abstract

“…Moreover, most cases resolve spontaneously after drug discontinuation. Nevertheless, we recommend aggressive treatment of neurologic, ocular, cardiac and renal sarcoidosis or hypercalcemia, because death [30,31], severe loss of vision, fatal arrhythmias, or insidious renal damage may ensue without therapy. …”

Section: Discussionmentioning

confidence: 99%

Two Cases of Interferon-Alpha-Induced Sarcoidosis Koebnerized along Venous Drainage Lines: New Pathogenic Insights and Review of the Literature of Interferon-Induced Sarcoidosis

Buss¹,

Cattin

Spring

et al. 2013

Dermatology

View full text Add to dashboard Cite

Sarcoidosis is a systemic granulomatous disorder of unknown origin commonly affecting the lung, the lymphoid system and the skin. We report here two cases of cutaneous sarcoidosis in two former intravenous drug users following interferon (IFN)-α and ribavirin therapy for chronic hepatitis C. Both patients developed skin sarcoidosis along venous drainage lines of both forearms, coinciding with the areas of prior drug injections. The unique distribution of the skin lesions suggests that tissue damage induced by repeated percutaneous drug injections represents a trigger for the local skin manifestation of sarcoidosis. Interestingly, skin damage was recently found to induce the local expression IFN-α, a well-known trigger of sarcoidosis in predisposed individuals. Here we review the literature on sarcoidosis elicited in the context of IFN-α therapy and propose a new link between the endogenous expression of IFN-α and the induction of disease manifestations in injured skin.

show abstract

Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis

Cooke

Kamal

Strengert

et al. 2017

QJM: An International Journal of Medicine

View full text Add to dashboard Cite

show abstract

Multisystem sarcoidosis in a patient on interferon-α therapy for chronic hepatitis C

Cited by 3 publications

References 15 publications

Interferon-induced sarcoidosis with uveitis as the initial symptom: a case report and review of the literature

Interferon-induced sarcoidosis with uveitis as the initial symptom: a case report and review of the literature

Two Cases of Interferon-Alpha-Induced Sarcoidosis Koebnerized along Venous Drainage Lines: New Pathogenic Insights and Review of the Literature of Interferon-Induced Sarcoidosis

Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis

Contact Info

Product

Resources

About